Table 2.

Geometric mean ratio (midazolam and secukinumab/midazolam) and 90% CIs for PK parameters (PK analysis set)

Parameter	Visit	n a	Adjusted geometric mean	Comparison (day/baseline)	Geometric mean ratio	90% CI for ratio
AUC0–12 h (hour·ng/mL)	Baseline	22	71.84
	Day 8	22	69.90	Day 8 vs. baseline	0.97	0.87−1.09
	Day 36	21	67.11	Day 36 vs. baseline	0.93	0.83−1.05
AUCinf (hour·ng/mL)	Baseline	22	82.17
	Day 8	21	81.70	Day 8 vs. baseline	0.99	0.88−1.12
	Day 36	20	79.35	Day 36 vs. baseline	0.97	0.85−1.09
Cmax (ng/mL)	Baseline	22	24.81
	Day 8	22	27.13	Day 8 vs. baseline	1.09	0.94−1.28
	Day 36	21	23.26	Day 36 vs. baseline	0.94	0.80−1.10

AUC_0–12 h, 0–12‐hour area under the concentration‐time curve; AUC_inf, area under the concentration‐time curve to infinity; CI, confidence interval; C_max, peak plasma concentration; PK, pharmacokinetic.

^a n = number of patients with nonmissing values. The log transformed primary PK parameters of C_max, AUC_0–12 h, and AUC_inf were analyzed using a mixed effect model with day as fixed and patients as random effect. Midazolam 5 mg was administered on baseline (reference), day 8 (test), and day 36 (test).